Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 5, 2006, Pages 1770-1778

  Okopień, Boguslaw ^a   Krysiak, Robert ^a   Herman, Zbigniew S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; FENOFIBRATE; FIBRINOGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIET; DRUG EFFECT; HEMOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CYTOKINES; DIET; FEMALE; FIBRINOGEN; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOSTASIS; HORMONES; HUMANS; INFLAMMATION; LIPIDS; LIPOPROTEINS; MALE; MIDDLE AGED; MONOCYTES; PROCETOFEN;

EID: 33646393509     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-1615     Document Type: Article

References (40)

1. Elisaf M 2002 Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18:269-276
2. Chen YE, Fu M, Zhang J, Zhu X, Lin Y, Akinbami MA, Song Q 2003 Peroxisome proliferator-activated receptors and the cardiovascular system. Vitam Horm 66:157-188
3. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH 2002 Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 112:275-280
4. Zhao SP, Ye HJ, Zhou HN, Nie S, Li QZ 2003 Gemfibrozil reduces release of tumor necrosis factor-α in peripheral blood mononuclear cells from healthy subjects and patients with coronary heart disease. Clin Chim Acta 332:61-67
5. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A 1998 Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790-793
6. Xu X, Otsuki M, Saito H, Sumitani S, Yamamoto H, Asanuma N, Kouhara H, Kasayama S 2001 PPARα and GR differentially down-regulate the expression of nuclear factor-κB-responsive genes in vascular endothelial cells. Endocrinology 142:3332-3339
7. Okopień B, Krysiak R, Haberka M, Herman ZS 2005 Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J Cardiovasc Pharmacol 45:314-320
8. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Łabuzek K, Herman ZS 2004 The effect of statins and fibrates on interferon-γ and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327-335
9. Avellone G, Di Garbo V, Cordova R, Piliego T, Raneli G, De Simone R, Bompiani GD 1995 Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coagul Fibrinolysis 6:543-548
10. Ushiroyama T, Ikeda A, Higashio S, Ueki M 2004 Coagulofibrinolytic assessment of effects of bezafibrate on hypertriglyceridemia in postmenopausal women. Blood Coagul Fibrinolysis 11:709-714
11. Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska-Wanat M, Kalina Z, Herman ZS 2001 Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther 39:551-557
12. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G 2000 Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 30:871-878
13. O'Neal DN, O'Brien RC, Timmins KL, Grieve GD, Lau KP, Nicholson GC, Kotowicz MA, Best JD 1998 Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabet Med 15:870-877
14. Skrha J, Stulc T, Hilgertova J, Weiserova H, Kvasnicka J, Ceska R 2004 Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur J Pharmacol 493:183-189
15. Koh KK, Yeal Ahn J, Hwan Han S, Kyu Jin D, Sik Kim H, Cheon Lee K, Kyun Shin E, Sakuma I 2004 Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 174:379-383
16. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT 2003 Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 170:315-323
17. Kowalski J, Okopien' B, Madej A, Zielinski M, Belowski D, Kalina Z, Herman ZS 2003 Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther 41:241-247
18. Ceriello A 2004 Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 147:803-807
19. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D 2002 Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-2072
20. Choi KM, Lee J, Lee KW, Seo JA, Oh JH, Kim SG, Kim NH, Choi DS, Baik SH 2004 Comparison of serum concentrations of C-reactive protein, TNF-α, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Res Clin Pract 64:99-106
21. Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H 2002 Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-α or its receptors. Diabetologia 45:805-812
22. Okopien B, Stachura-Kulach A, Kulach A, Kowalski J, Zielinski M, Wisniewska-Wanat M, Sierant M, Kalina Z, Herman ZS 2003 The risk of atherosclerosis in patients with impaired glucose tolerance. Res Commun Mol Pathol Pharmacol 113- 114:87-95
23. Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini MP, Costantino F, Ruotolo G, Luzi L, Perseghin G 2003 Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care 26:2883-2889
24. Okopień B, Krysiak R, Herman ZS 2004 Effect of monthly atorvastatin treatment on hemostasis. Int J Clin Pharmacol Ther 42:589-593
25. Madej A, Okopień B, Łabuzek K, Krysiak R, Herman ZS 2004 The reactivity of macrophages in essential hypertension. XVth International Congress of the Polish Pharmacological Society. Pol J Pharmacol 56(Suppl):156.
26. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S 2004 Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109:2197-2202
27. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z 2004 Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther 42:212-217
28. Inoue I, Takahashi K, Katayama S, Akabane S, Negishi K, Suzuki M, Ishii J, Kawazu S 2004 Improvement of glucose tolerance by bezafibrate in nonobese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 25:199-205
29. Krysiak R, Okopień B, Herman ZS 2003 Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63:1821-1854
30. Keating GM, Ormrod D 2002 Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 62:1909-1944
31. Asplund-Carlson A 1996 Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. J Cardiovasc Risk 3:385-390
32. Vega GL, Cater NB, Hadizadeh 3rd DR, Meguro S, Grundy SM 2003 Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther 74:236-244
33. Despres JP, Lemieux I, Robins SJ 2004 Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 64:2177-2198
34. The FIELD Study Investigators 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849 -1861.
35. Calabro P, Willerson JT, Yeh ET 2003 Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108:1930-1932
36. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T 2004 Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103:4188-4194
37. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H, Kataoka H, Nishi E, Horiuchi H, Arai H, Yokode M 2001 Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci 947:199-205
38. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fievet C, Lefebvre P, Staels B 2005 Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor α modulation. Arterioscler Thromb Vasc Biol 25:585-591
39. Holness MJ, Smith ND, Greenwood GK, Sugden MC 2003 Acute (24 h) activation of peroxisome proliferator-activated receptor-α (PPARα) reverses high-fat feeding-induced insulin hypersecretion in vivo and in perifused pancreatic islets. J Endocrinol 177:197-205
40. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B 2001 PPARα agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103:207-212